Glimepiride
A sulfonylurea oral antidiabetic used to improve blood sugar control in type 2 diabetes by stimulating insulin release from the pancreas and enhancing insulin's action in peripheral tissues. It is often used alone or in combination with insulin or other diabetes medications when lifestyle modifications are insufficient. Regular monitoring of blood glucose is important to avoid hypoglycemia.
분자량
490.6000 g/mol
LogP
3.90
TPSA
133.00 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
2D 구조
Cite this structure
Embed this structure
SMILES
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
InChI
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-
Molecular Formula
C24H34N4O5S
HBD / HBA
3 / 5
회전 가능 결합
7
무거운 원자
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
A sulfonylurea oral antidiabetic used to improve blood sugar control in type 2 diabetes by stimulating insulin release from the pancreas and enhancing insulin's action in peripheral tissues. It is often used alone or in combination with insulin or other diabetes medications when lifestyle modifications are insufficient. Regular monitoring of blood glucose is important to avoid hypoglycemia.
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Yes, Glimepiride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1481. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3476. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="glimepiride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/glimepiride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/glimepiride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/glimepiride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="glimepiride"></drugfyi-drug>